Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee.

Ethan D BorreAima A AhonkhaiKyu-Young Kevin ChiAmna OsmanKrista ThayerAnna K PersonAndrea WeddleClare F FlanaganApril C PettitDavid ClossMia CottonAllison Lorna AgwuMichelle S CespedesAndrea L CiaranelloGregg S GonsalvesEmily P HyleA David PaltielKenneth A FreedbergAnne M Neilan

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Redirecting HIV prevention funding in Tennessee would greatly harm CDC priority populations while conferring minimal benefits to new priority populations.

Keyphrases

human immunodeficiency virus
hepatitis c virus
antiretroviral therapy
hiv infected
genetic diversity
hiv aids
hiv positive
cell cycle
hiv testing